Skip to main content
Retour
MLTX logo

MoonLake Immunotherapeutics

Qualité des données : 100%
MLTX
NASDAQ Healthcare Biotechnology
16,87 €
▲ 0,60 € (3,69%)
Cap. Boursière : 1,21B
Fourchette du Jour
16,50 € 17,32 €
Fourchette 52 Semaines
5,95 € 62,75 €
Volume
774 940
Moyenne 50J / 200J
16,85 € / 29,02 €
Clôture Précédente
16,27 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -5,3 0,4
P/B 4,0 2,9
ROE % -60,5 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,3 0,2

Objectif de Cours des Analystes

Hold
19,88 € +17.8%
Low: 8,00 € High: 35,00 €
BPA Prévisionnel
-3,65 €
CA Est.
0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,74 €
1,74 € – 4,15 €
900 M 6
FY2029 -0,48 €
-0,72 € – -0,30 €
450 M 6
FY2028 -2,59 €
-4,77 € – -0,86 €
140 M 8

Points Clés

Debt/Equity of 0,25 — conservative balance sheet
Negative free cash flow of -196,04M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-60,51%
ROIC-48,30%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,25
Current Ratio9,27
Interest Coverage-33,78

Valorisation

P/E Ratio
-5,32
P/B Ratio3,97
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -227,32M
ROE -60,51% ROA -53,56%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -196,04M
ROIC -48,30% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,25 Current Ratio 9,27
Interest Coverage -33,78 Dividend Yield 0,00%
Valuation
P/E Ratio -5,32 P/B Ratio 3,97
P/S Ratio N/A PEG Ratio -0,04
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,21B Enterprise Value 951,24M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -227,32M -118,94M -36,01M -49,97M -53,64M
EPS (Diluted) -3,53 -1,89 -0,73 -2,20 -1,45
Gross Profit -2,62M 0,0 0,0 0,0 -4 971,0
Operating Income -244,83M -143,09M -54,12M -65,06M -53,58M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 424,43M 477,93M 526,54M 76,84M 9,68M
Total Liabilities 119,95M 24,54M 13,05M 8,08M 21,33M
Shareholders' Equity 304,48M 446,83M 495,68M 48,90M -11,65M
Total Debt 75,71M 2,83M 3,70M 282 580,0 15,00M
Cash & Equivalents 334,52M 180,43M 451,17M 39,51M 8,04M
Current Assets 421,69M 474,29M 514,17M 76,51M 9,64M
Current Liabilities 45,48M 22,46M 9,97M 7,67M 21,09M